Hypertriglyceridemia - Pipeline Review, H2 2016

Hypertriglyceridemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides an overview of the Hypertriglyceridemia (Metabolic Disorders) pipeline landscape.

Hypertriglyceridemia is a condition in which triglyceride levels are elevated. Causes include diabetes mellitus, obesity, family history and sedentary habits. Symptoms include gastrointestinal pain, difficulty breathing, memory loss, dementia, xanthelasmas and corneal arcus. Treatment includes diuretics, beta-blockers, estrogen therapy and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertriglyceridemia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertriglyceridemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertriglyceridemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypertriglyceridemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 1, 2, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hypertriglyceridemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertriglyceridemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypertriglyceridemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypertriglyceridemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypertriglyceridemia (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypertriglyceridemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypertriglyceridemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Hypertriglyceridemia Overview
Therapeutics Development
Pipeline Products for Hypertriglyceridemia - Overview
Pipeline Products for Hypertriglyceridemia - Comparative Analysis
Hypertriglyceridemia - Therapeutics under Development by Companies
Hypertriglyceridemia - Therapeutics under Investigation by Universities/Institutes
Hypertriglyceridemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hypertriglyceridemia - Products under Development by Companies
Hypertriglyceridemia - Products under Investigation by Universities/Institutes
Hypertriglyceridemia - Companies Involved in Therapeutics Development
Acasti Pharma Inc
Akcea Therapeutics Inc
Allergan Plc
Alnylam Pharmaceuticals Inc
Arisaph Pharmaceuticals Inc
AstraZeneca Plc
BASF SE
Cardax Inc
Catabasis Pharmaceuticals Inc
Celon Pharma SA
CymaBay Therapeutics Inc
Gemphire Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Kyorin Pharmaceutical Co Ltd
LipimetiX Development Inc
Matinas BioPharma Holdings Inc
Sancilio & Company Inc
Zydus Cadila Healthcare Ltd
Hypertriglyceridemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEM-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AEM-2814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALN-AC3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALN-ANG - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit ANGPTL4 for Hypertriglyceridemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARI-3037MO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bezafibrate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BioE-1115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BSN-272 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-2000 Series - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-2003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDX-085 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gemcabene calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icosabutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-ANGPTL3LRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-APOCIIILRX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LTPO-3FA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAT-9001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKPL-66 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omega-3-carboxylic acids - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seladelpar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Hypertriglyceridaemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Dyslipidemic and Vascular Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volanesorsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypertriglyceridemia - Dormant Projects
Hypertriglyceridemia - Discontinued Products
Hypertriglyceridemia - Product Development Milestones
Featured News & Press Releases
Dec 19, 2016: Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen
Sep 14, 2016: Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data
Jun 11, 2016: New Scientific Data of Investigational Lipaglyn (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions
May 16, 2016: Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen
Mar 23, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia
Feb 24, 2016: SPCI Announces US PTO Allowance of Patent Claims
Nov 18, 2015: Zydus announces clinical trials of Saroglitazar in patients with Severe Hypertriglyceridemia in USA
Jul 29, 2015: Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine
May 25, 2015: Phase 2a Clinical Study of Icosabutate in Patients with Severe Hypertriglyceridemia
Apr 22, 2015: CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
Mar 02, 2015: Acasti Receives Full Data for Phase II TRIFECTA Trial
Sep 30, 2014: Acasti Announces Positive Top-Line Pharmacokinetic Results
Sep 29, 2014: Acasti Reports Successful CaPre Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C
Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APOCIIIRX At European Society of Cardiology Congress 2014
Jul 24, 2014: Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hypertriglyceridemia, H2 2016
Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Hypertriglyceridemia - Pipeline by Acasti Pharma Inc, H2 2016
Hypertriglyceridemia - Pipeline by Akcea Therapeutics Inc, H2 2016
Hypertriglyceridemia - Pipeline by Allergan Plc, H2 2016
Hypertriglyceridemia - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016
Hypertriglyceridemia - Pipeline by Arisaph Pharmaceuticals Inc, H2 2016
Hypertriglyceridemia - Pipeline by AstraZeneca Plc, H2 2016
Hypertriglyceridemia - Pipeline by BASF SE, H2 2016
Hypertriglyceridemia - Pipeline by Cardax Inc, H2 2016
Hypertriglyceridemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016
Hypertriglyceridemia - Pipeline by Celon Pharma SA, H2 2016
Hypertriglyceridemia - Pipeline by CymaBay Therapeutics Inc, H2 2016
Hypertriglyceridemia - Pipeline by Gemphire Therapeutics Inc, H2 2016
Hypertriglyceridemia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
Hypertriglyceridemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
Hypertriglyceridemia - Pipeline by LipimetiX Development Inc, H2 2016
Hypertriglyceridemia - Pipeline by Matinas BioPharma Holdings Inc, H2 2016
Hypertriglyceridemia - Pipeline by Sancilio & Company Inc, H2 2016
Hypertriglyceridemia - Pipeline by Zydus Cadila Healthcare Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Hypertriglyceridemia - Dormant Projects, H2 2016
Hypertriglyceridemia - Dormant Projects (Contd..1), H2 2016
Hypertriglyceridemia - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Hypertriglyceridemia, H2 2016
Number of Products under Development for Hypertriglyceridemia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook